Flozins - New Revolution Has Started

Dear Colleagues,

SGLT2 inhibitors (flozins) have well-established clinical indications in the treatment of type 2 diabetes, chronic kidney disease, heart failure with reduced and preserved left ventricular ejection fraction. Currently, the important role of SGLT-2 inhibitors is also being discovered in the treatment of arterial hypertension, metabolic-associated fatty liver disease, anemia and long-COVID syndromes. SGLT2 inhibitors freed themselves from the odium of nephrological-diabetological-cardiovascular drugs, with recent data showing that their use is multidirectional and related to presence of SGLTs present in many organs. The revolutionary role of SGLT2 inhibitors was summarized by prof. Eugene Braunwald - the legend of world cardiology, stating that these drugs are "the statins of the 21st century". We invite you to submit review papers, systematic reviews, meta-analyses and original studies for our special issue "Flozins - New Revolution Has Started", in which we would like to collect the latest and most interesting data on SGLT2 inhibitors.

Prof. Dr. Krzysztof J. Filipiak
Dr. Aleksandra Gąsecka
Topic Editors

Stanisław Surma
Topic Editor Assistant